Targets › NDUFS8
1 program from 1 company in 23 trials: 11 Phase 2, 5 Phase 1, 5 Phase 3, 2 Phase 4; Neurology, Cardiovascular, Genitourinary.
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor. Essential for the catalytic activity and assembly of complex I. (UniProt, O00217)
Open in Phaseline: the race on NDUFS8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Boryung Pharmaceutical | Metformin Hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | MT-ND6, NDUFA10, NDUFS8, MT-ND4L, NDUFA6 | Phase 1 | Diabetes Mellitus; Diabete Mellitus; Depression; Polycystic Ovary Syndrome … | – |
Anatomic Stage I Breast Cancer AJCC v8 (2) Erythroplakia (2) Diabetes Mellitus (1) Diabete Mellitus (1) Depression (1) Polycystic Ovary Syndrome (1) Breast Atypical Ductal Hyperplasia (1) Non Small Cell Lung Cancer (1) Medulloblastoma, Childhood (1) Pre-Eclampsia Onset Less Than 37 Weeks (1) Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia (1) Lung Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.